Lupin, Fuji in agreement for commercialisation of Nextstellis in Vietnam and Philippines
IMT News Desk
Nextstellis is a novel combination medication comprising drospirenone (DRSP) and estetrol (E4), indicated for use by women of reproductive age to prevent pregnancy Lupin has signed a license and supply agreement with OLIC (Thailand) (OLIC), a subsidiary of the renowned Japanese pharmaceutical company Fuji Pharma Co (Fuji), for marketing Nextstellis (drospirenone and estetrol tablets) in Vietnam and the Philippines.Nextstellis is a novel combination medication comprising drospirenone (DRSP) and estetrol (E4), indicated for use by women of reproductive age to prevent pregnancy. “We are delighted to collaborate with Fuji and OLIC to offer NextstellisTM to our patients in Vietnam and the Philippines. This new addition to our Women’s Health portfolio will strengthen our commitment to expand healthcare options worldwide,” said Dr Fabrice Egros, President – Corporate Development and Growth Markets, Lupin.
